Home » Stocks » IOVA

Iovance Biotherapeutics, Inc. (IOVA)

Stock Price: $22.52 USD -0.40 (-1.75%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $22.13 -0.39 (-1.73%) Jul 29, 4:18 PM
Market Cap 3.47B
Revenue (ttm) n/a
Net Income (ttm) -265.44M
Shares Out 147.37M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $22.52
Previous Close $22.92
Change ($) -0.40
Change (%) -1.75%
Day's Open 22.95
Day's Range 22.49 - 23.51
Day's Volume 1,375,800
52-Week Range 15.88 - 54.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...

1 week ago - GlobeNewsWire

The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.

3 weeks ago - The Motley Fool

Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.

4 weeks ago - Zacks Investment Research

SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced tha...

1 month ago - GlobeNewsWire

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced clinical data for its tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC).  The co...

1 month ago - Benzinga

21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy

1 month ago - GlobeNewsWire

This biotech's fumble has caught the attention of a fund manager known for making innovative investments.

1 month ago - The Motley Fool

Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced updated clinical data for lifileucel from Cohort 2 of C-144-01 clinical study in patients with advanced melanoma. Data were presented at the ASCO 202...

1 month ago - Benzinga

Median Duration of Response (DOR) Not Reached at 33.1 Months  of Median Study Follow Up in Cohort 2 in C-144-01 Study

1 month ago - GlobeNewsWire

86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study

1 month ago - GlobeNewsWire

SAN CARLOS, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

1 month ago - GlobeNewsWire

Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc (NASDAQ: IOVA) will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunoth...

2 months ago - Benzinga

The CEO's unexplained departure has left investors scratching their heads.

2 months ago - The Motley Fool

A couple of the ARK exchange-traded funds run by ETF star Cathie Wood made huge purchases on Thursday.

2 months ago - 24/7 Wall Street

SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to submit your losses now. The firm is investigating possib...

2 months ago - PRNewsWire

Yesterday the FDA asked Iovance Biotherapeutics Inc (NASDAQ: IOVA) for more data on the assays for lifileucel US application. Now the company announced additional clinical data for lifileucel alone and ...

2 months ago - Benzinga

With the trading day almost halfway over, the markets had made a handy recovery on Thursday, bouncing off the lows of last week.

Other stocks mentioned: MRK, MU, NVDA, CC, TGT, TREE, WEN
2 months ago - 24/7 Wall Street

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

2 months ago - Zacks Investment Research

MILWAUKEE, May 20, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Iovance (NASDAQ: IOVA).  The investigation results from inaccurate statements Iovance may have...

2 months ago - PRNewsWire

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $IOVA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors

2 months ago - Business Wire

86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study

2 months ago - GlobeNewsWire

In a brief statement, Iovance Biotherapeutics Inc (NASDAQ: IOVA) company divulged that the FDA wants to see more data on the assays used to ensure each batch of its tumor-infiltrating lymphocyte therapy...

2 months ago - Benzinga

The company is delaying the FDA approval filing for cell therapy lifileucel.

2 months ago - The Motley Fool

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has received regulatory feedback from the FDA on its potency assays for lifileucel. Following FDA feedback, Iovance will have to submit additional assay data a...

2 months ago - Benzinga

SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announce...

2 months ago - GlobeNewsWire

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up

2 months ago - GlobeNewsWire

Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.

2 months ago - Zacks Investment Research

Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors

2 months ago - GlobeNewsWire

SAN CARLOS, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announce...

2 months ago - GlobeNewsWire

Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study

3 months ago - GlobeNewsWire

SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report ...

3 months ago - GlobeNewsWire

Median Duration of Response Not Reached at 28.1 Months  of Median Study Follow Up in Cohort 2 of C-144-01 Study

3 months ago - GlobeNewsWire

TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.

3 months ago - The Motley Fool

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...

4 months ago - GlobeNewsWire

SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...

4 months ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, AKBA, ARAV, BGNE, IMO ...
4 months ago - 24/7 Wall Street

SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...

4 months ago - GlobeNewsWire

Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

5 months ago - Zacks Investment Research

Advancing First-in-Class TIL Cell Therapy for Solid Tumors Advancing First-in-Class TIL Cell Therapy for Solid Tumors

5 months ago - GlobeNewsWire

SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...

5 months ago - GlobeNewsWire

SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

6 months ago - GlobeNewsWire

Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifileucel, are ...

7 months ago - Seeking Alpha

SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

7 months ago - GlobeNewsWire

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

7 months ago - GlobeNewsWire

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...

7 months ago - GlobeNewsWire

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

8 months ago - Zacks Investment Research

About IOVA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastat... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Maria Fardis
Employees
241
Stock Exchange
NASDAQ
Ticker Symbol
IOVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is 40.31, which is an increase of 79.00% from the latest price.

Price Target
$40.31
(79.00% upside)
Analyst Consensus: Buy